You are now leaving www.admabiologics.com

The link you have selected will take you outside of ADMA Biologics corporate website. The site you will be entering is intended for U.S. audiences only. Do you wish to continue?

About ADMA Biologics

End-to-end Commercial Biopharmaceutical Company

ADMA Biologics is an end-to-end biopharmaceutical company with three FDA-licensed approved products including ASCENIV™ (Immune Globulin Intravenous - slra, Human), BIVIGAM® (Immune Globulin Intravenous, Human), and NABI-HB® (hepatitis B immune globulin, human). ADMA’s mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations.

ADMA Operates One of the Few Plasma Fractionation Facilities in the United States.

  • Successful plant inspections and drug approvals received
  • Track record of receiving FDA approval for plasma collection centers
  • 400,000L annual capacity plasma fractionation and purification plant operating in FDA compliance
  • ADMA BioCenters subsidiary provides a portion of source plasma and long term supply contracts are in place
  • Strong patent portfolio across hyperimmune Ig landscape including ASCENIV™
  • FDA-approved products including ASCENIV™ (Immune Globulin Intravenous – slra, Human), BIVIGAM® (Immune Globulin Intravenous, Human) and Nabi-HB® (Hepatitis B Immune Globulin, Human)
  • Platform for developing additional hyperimmune and specialty Ig products
  • Internal R&D capabilities

Our Values

ADMA Biologics is a biopharmaceutical company relentlessly committed to creating novel products for immunodeficient patients at risk for infection. It is our devotion to this underserved population that fuels us.

HUMAN

HUMAN

We make human connection a priority in our products, our patients, and our people.

COURAGEOUS

COURAGEOUS

We take on the challenges others won’t by embracing rare diseases.

DYNAMIC

DYNAMIC

We are relentless in transforming groundbreaking science into meaningful action.

TENACIOUS

TENACIOUS

We are tireless in our pursuit of perfection because people’s lives are in our hands.

Through our relentless commitment to improving people’s lives, we are changing the future with immunotechnology.

Poised for Growth

Beyond the present focus on the commercial development of ASCENIV™ and expansion of our plasma collection facilities, there are a number of additional opportunities for growth, including:

  • Evaluating strategies for potential manufacturing capacity expansion.
  • Exploring additional clinical research and commercial opportunities to address unmet needs for immunocompromised patients.
  • Developing additional plasma-derived products through direct R&D and potential licensing opportunities. These follow-on products may include infectious disease specific intravenous immune globulin (IVIG) product candidates targeting immunocompromised patients as well as transplant patients.
  • ADMA Biologics offers a full suite CDMO and CMO partnering opportunities.
More For Investors